**This article has been corrected:** Due to errors in figure preparation, the data for [Table 3](#T1){ref-type="table"} was listed incorrectly. It has now been updated with corrected numbers (see text in [Table 3](#T1){ref-type="table"}) and the resulting graphs ([Figure 2A](#F1){ref-type="fig"} and [2B](#F1){ref-type="fig"}) have been updated as well. In addition, the reference list for this paper was accidentally alphabetized during the production process, while citation numbers within the article remained according to first-mention. In this correction, the entire references list has been corrected. We include the reference list in their order of mention so that the citation number in the article corresponds to the reference number in the list.
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###### Summary of pharmacokinetics parameters for GDC-0853 on day 1 and day 15 (cohorts 1, 2, and 3, with 100, 200, and 400-mg GDC-0853, respectively)

  Dose               Day 1 T~1/2~ (hr) Mean (%CV)   Day 1 T~max~^a^ (hr) Median (range)   Day 1 C~max~ (μM) Mean (%CV)   Day 1 AUC~0-inf~ (hr•μM) Mean (%CV)   Day 1 AUC~0-24~ (hr\*μM) Mean (%CV)   Day 15 T~max~^a^(hr) Median (range)   Day 15 C~max~ (μM) Mean (%CV)   Day 15 AUC~0-\ 24~ (hr•μM) Mean (%CV)   Day 15 Accumulation Ratio Mean (%CV)
  ------------------ ------------------------------ ------------------------------------- ------------------------------ ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------- --------------------------------------- --------------------------------------
  100 mg (*n* = 6)   13.7 (59.4)                    2.07 (1.02--3.00)                     0.119 (113.0)                  0.861 (58.5)                          0.670 (77.4)                          2.97 (1.08--7.50)                     0.235 (124)                     1.20 (107)                              1.78 (58.4)
  200 mg (*n* = 9)   6.62 (41.6)                    1.85 (0.833-- 8.03)                   0.571 (90.5)                   3.42 (65.2)                           2.54 (76.5)                           2.10 (0.917-- 8.00)                   0.614 (106)                     2.83 (63.2)                             1.44 (77.9)
  400 mg (*n* = 9)   7.29 (16.1)                    1.17 (1.00--3.00)                     1.44 (58.3)                    7.57 (65.2)                           6.95 (65.8)                           1.05 (0.967-- 4.00)                   1.39 (41.9)                     7.74 (45.6)                             1.91 (102)

AUC~0-24hr~ = area under the concentration time curve from Hour 0 to Hour 24;

CAUC~0inf~ = area under the concentration time-curve from time 0 to infinity;

C~max~ = maximum plasma concentration; CV% = coefficient of variation; t~1/2~ = half-life;

T~max~ = time to maximum plasma concentration.

aT~max~ was reported as median and range.
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